Simulations Plus Acquires Lixoft

Simulations Plus

Simulations Plus, Inc. (Nasdaq: SLP), a Lancaster, Calif.-based provider of simulation and modeling software for pharmaceutical discovery and development, acquired Lixoft, a Paris, France-based provider of software solutions to reduce the cost and increase the success rate of new drug development.

Under the terms of the deal, Simulations Plus will pay the shareholders of Lixoft consideration of cash and stock of up to $16.5m, comprised of $11m paid upon close plus an earnout of up to an additional $5.5m over the next two years, based on the revenue growth and profitability of Lixoft over this time frame.

Founded in 2011 by Jérôme Kalifa and Marc Lavielle, Lixoft brings advances to the modeling and simulation community in user-friendly tools designed to break the preclinical/clinical/vigilance divides for modeling and simulation and allow all stages of drug development to share information and synthesize them in studies. The Monolix Suite is a population PKPD modeling solution for pharmacometricians. It supports modeling projects from the first data exploration to clinical trial simulations. For the calendar year 2019, the company’s revenues were approximately $3.4 million with net earnings of approximately $1.7 million and a staff of 11 employees.

Led by Shawn O’Connor, chief executive officer, Simulations Plus is a developer of drug discovery and development software as well as a provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. The software is licensed and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide.

FinSMEs

03/04/2020

Join the discussion